Myriad Genetics Partners with SOPHiA GENETICS for Innovative Liquid Biopsy Diagnostic Development

Myriad Genetics and SOPHiA GENETICS Unite for Liquid Biopsy Companion Diagnostic Development

Myriad Genetics, a prominent player in molecular diagnostic testing, announces a strategic collaboration with SOPHiA GENETICS, an AI technology company. This partnership aims to develop a global liquid biopsy companion diagnostic (CDx) test specifically designed for pharmaceutical companies. By leveraging Myriad’s advanced laboratory capabilities in the U.S. and SOPHiA’s vast network of over 800 connected institutions across more than 70 countries, the collaboration is set to facilitate the worldwide deployment of innovative testing solutions. The emphasis on enhancing the patient experience throughout the cancer care continuum underscores the commitment both companies share toward improving healthcare outcomes for patients.

Central to this collaboration is the initial focus on the liquid biopsy application, MSK-ACCESS®, which is powered by SOPHiA DDM™. This application is capable of detecting actionable genomic alterations from a single blood draw, utilizing sophisticated algorithms to analyze circulating tumor DNA (ctDNA). The integration of Myriad’s expertise in regulatory submissions within the U.S. with SOPHiA’s management of submissions outside the U.S. marks a significant move toward establishing a streamlined process for bringing these tests to market. As both companies work closely on development activities, they aim to create comprehensive CDx solutions that not only enhance the capabilities of biopharma partners but also foster advancements in personalized medicine.

Sam Raha, President and CEO of Myriad Genetics, articulates the collaboration’s potential to significantly benefit patients while driving growth in the company’s CDx programs. Jurgi Camblong, Co-founder and CEO of SOPHiA GENETICS, adds that this partnership represents a landmark moment for the industry, merging the strengths of a specialized lab with a global testing network. This synergy is expected to broaden access to cutting-edge oncology testing, paving the way for a new hybrid model in companion diagnostics. Both companies are set to share their insights and future plans during a panel discussion at the World CB and CDx Summit in Boston, highlighting their collaborative efforts to advance liquid biopsy solutions and personalized healthcare.

The collaboration between Myriad Genetics and SOPHiA GENETICS exemplifies the growing trend of integrating advanced technology with molecular diagnostics to enhance cancer care. By combining their respective strengths, the companies position themselves at the forefront of innovation in the oncology testing landscape. This partnership not only reflects their commitment to improving patient outcomes but also showcases the potential of collaborative efforts in addressing the complexities of modern healthcare challenges.